Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00959296 · ClinicalTrials.gov registry record

Implantable Systems Performance Registry

A clinical trial of Deep Brain Stimulation and Spinal Cord Stimulation, sponsored by MedtronicNeuro.

Completed
Registry status
10,981
Enrollment target
20
Study locations

NCT00959296: Completed study of Deep Brain Stimulation and Spinal Cord Stimulation, sponsored by MedtronicNeuro.

NCT00959296 is a study of Deep Brain Stimulation and Spinal Cord Stimulation that has completed, run by MedtronicNeuro. The registered enrollment target is 10,981 participants, above the 85-participant average among 15 other Deep Brain Stimulation trials with a reported enrollment target (12819% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00959296, a study of Deep Brain Stimulation and Spinal Cord Stimulation, has completed, sponsored by MedtronicNeuro.

COMPLETED
Registry status
10,981 participants
Enrollment target
20
Study locations

Study Summary

The Implantable Systems Performance Registry (ISPR) was developed to evaluate the long-term reliability and performance of market-released Medtronic Neuromodulation infusion and stimulation products. Completion Notice: The ISPR was created by Medtronic to monitor the performance of commercially available products. This registry was initially designed to track performance of Medtronic's implantable infusion and spinal cord stimulation systems beginning in August 2003 and June 2004, respectively. Medtronic DBS Systems were added to the ISPR in June 2009, and Sacral Neuromodulation Systems in April 2010. Medtronic retired the ISPR in April 2016 and merged the data collected from this registry into the Product Surveillance Registry (PSR). Please refer to that record, Clinical Trials identifier: NCT01524276, for further information.

Primary Outcome

To quantify and compare the rates of device-related events for market-released Medtronic Neuromodulation infusion and stimulation devices

Conditions Studied

Deep Brain Stimulation Spinal Cord Stimulation Drug Infusion (Implantable Pumps) Sacral Neuromodulation

Interventions

  • DEVICE Various

Study Locations (20)

California

  • - Aliso Viejo
  • - Los Angeles
  • - Napa
  • - Palm Springs
  • - Pasadena
  • - San Diego
  • - Upland

Florida

  • Site recruiting for sacral nerve stimulation - Bradenton
  • - Merritt Island
  • - Ocala

Indiana

  • - Evansville
  • - Muncie
  • - South Bend

Georgia

  • - Atlanta
  • - Gainesville

Illinois

  • - Bloomington
  • - Chicago

Alabama

  • - Huntsville

Arizona

  • - Scottsdale

District of Columbia

  • - Washington D.C.

Trial Details

FieldValue
Enrollment Target 10,981 participants
Start Date 2003-08
Est. Completion 2016-09-27
MedtronicNeuro

51 total trials

What the finished NCT00959296 record still lists

NCT00959296 is an observational study that tracks outcomes without assigning an intervention. Its 10,981 participants enrollment target places it among the larger protocols in the corpus, above the 85-participant average among 15 other Deep Brain Stimulation trials with a reported enrollment target (12819% higher).

The record links to 4 conditions, with Deep Brain Stimulation appearing as the primary indexed condition, and to 1 intervention - of which Various is the first listed.

NCT00959296 names 20 study sites across 8 states, led by California, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT00959296 about?

NCT00959296 is a clinical study titled "Implantable Systems Performance Registry". The Implantable Systems Performance Registry (ISPR) was developed to evaluate the long-term reliability and performance of market-released Medtronic Neuromodulation infusion and stimulation products. Completion Notice: The ISPR was created by Medtronic to monitor the performance of commercially ava...

What is the current status of trial NCT00959296?

This trial is currently completed. The enrollment target is 10,981 participants. The study started on 2003-08. Estimated completion is 2016-09-27.

What conditions does trial NCT00959296 study?

This clinical trial studies the following conditions: Deep Brain Stimulation, Spinal Cord Stimulation, Drug Infusion (Implantable Pumps), Sacral Neuromodulation.

What interventions are being tested in trial NCT00959296?

The interventions under investigation include: Various (DEVICE).

Who is sponsoring clinical trial NCT00959296?

This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00959296 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Deep Brain Stimulation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00959296's enrollment target sits among peer trials

10,981 1st of 15 higher than 15 of 15 other Deep Brain Stimulation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Deep Brain Stimulation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06531824 · 11,000 participants · Phase 3

    EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  • NCT07136012 · 11,000 participants · Phase 3

    OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  • NCT07181109 · 11,000 participants · Phase 3

    Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  • NCT06736951 · 10,890 participants · NA

    Modifying the Inpatient Environment to Reduce Delirium in Older Adults

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00959296, the US trial registry maintained by the National Library of Medicine. NCT00959296 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.